{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:22:37Z","timestamp":1784132557780,"version":"3.55.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-sa\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>This study aimed to assess whether clinical complete response (cCR) criteria developed for neoadjuvant chemoradiotherapy (NACRT) are applicable to patients with proficient mismatch repair locally advanced rectal cancer (LARC) who are treated with NACRT combined with immunotherapy (NAICRT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study included 49 LARC patients who received NAICRT and 128 who received NACRT. Clinical response was assessed using two established criteria: the Memorial Sloan Kettering Cancer Center (MSKCC) criteria and the Chinese Watch-and-Wait Database (CWWD) criteria. These criteria integrate findings from digital rectal examination, endoscopy, MRI, and, optionally, carcinoembryonic antigen levels and biopsy results. Pathological complete response (pCR), determined from surgical specimens, was used as the reference standard. The diagnostic performance of these criteria in predicting pCR was evaluated using sensitivity, specificity, accuracy, and area under the curve (AUC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among the 177 patients, 54 achieved pCR (18 in the NAICRT group and 36 in the NACRT group). MSKCC and CWWD criteria showed comparable performance in the NACRT and NAICRT groups, respectively. Sensitivities were 0.11 and 0.28; specificities, 0.99 and 1.00; accuracies, 0.74 and 0.73; and AUCs, 0.55 and 0.64, with no significant differences between groups. Endoscopy demonstrated sensitivities of 0.28 and 0.61, specificities of 0.96 and 0.90, accuracies of 0.77 and 0.80, and AUCs of 0.67 and 0.76 in the NACRT and NAICRT groups, respectively, with a significant difference in sensitivity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =\u00a00.02). MRI showed sensitivities of 0.50 and 0.39, specificities of 0.91 and 0.90, accuracies of 0.80 and 0.71, and AUCs of 0.71 and 0.65, without significant differences.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The cCR assessment criteria originally developed for NACRT are also applicable to NAICRT patients, showing excellent specificity but suboptimal sensitivity, which may lead to overtreatment of patients with actual pCR. Future studies should focus on enhancing sensitivity to better support organ preservation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000002795","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:00:15Z","timestamp":1750680015000},"page":"6604-6613","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Applicability of cCR assessment criteria in pMMR rectal cancer patients treated with neoadjuvant chemoradiotherapy combined with immunotherapy"],"prefix":"10.1097","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-3204","authenticated-orcid":false,"given":"Junpeng","family":"Pei","sequence":"first","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiushi","family":"Dong","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuye","family":"Gao","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglin","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Xie","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Qu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjiu","family":"Chen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouxin","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwen","family":"Wu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Unit III, Gastrointestinal Cancer Center, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.2023.41.4_suppl.248","article-title":"Pretreatment risk prediction for distant metastasis in locally advanced rectal cancer","volume":"41","author":"Song","year":"2023","journal-title":"J Clin Oncol"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"e2414702","DOI":"10.1001\/jamanetworkopen.2024.14702","article-title":"Treatment of locally advanced rectal cancer in the era of total neoadjuvant therapy: a systematic review and network meta-analysis","volume":"7","author":"Turri","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/SLA.0000000000002719","article-title":"Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage III rectal cancer","volume":"269","author":"Karagkounis","year":"2019","journal-title":"Ann Surg"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"e2030097","DOI":"10.1001\/jamanetworkopen.2020.30097","article-title":"Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis","volume":"3","author":"Kasi","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1245\/s10434-017-5873-8","article-title":"Pathologic complete response rates after neoadjuvant treatment in rectal cancer: an analysis of the national cancer database","volume":"24","author":"Lorimer","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/SLA.0000000000005507","article-title":"Intentional watch and wait or organ preservation surgery following neoadjuvant chemoradiotherapy plus consolidation CAPEOX for MRI-defined low-risk rectal cancer: findings from a prospective phase 2 Trial (PKUCH-R01 Trial, NCT02860234)","volume":"277","author":"Wang","year":"2023","journal-title":"Ann Surg"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"R10-20260109","first-page":"100082","article-title":"Transparency in the reporting of artificial intelligence \u2013 the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(22)00439-3","article-title":"Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study","volume":"8","author":"Chen","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/j.annonc.2021.05.054","article-title":"SO-30 Efficacy and safety of neoadjuvant short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma: Averectal study","volume":"32","author":"Shamseddine","year":"2021","journal-title":"Ann Oncol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamasurg.2023.7996","article-title":"Total neoadjuvant therapy with PD-1 blockade for high-risk proficient mismatch repair rectal cancer","volume":"159","author":"Li","year":"2024","journal-title":"JAMA Surg"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"e003554","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"key":"R22-20260109","first-page":"301","article-title":"Wait Database Research Cooperation G, Chinese Society Of Colorectal S, Chinese Medical A, Colorectal Cancer Physician Specialty C, Colorectal Cancer C. [Chinese expert consensus on the watch and wait strategy in rectal cancer patients after neoadjuvant treatment (2024 version)]","volume":"27","author":"Chinese","year":"2024","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1245\/s10434-015-4687-9","article-title":"Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and mri: selection for organ-saving treatment","volume":"22","author":"Maas","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1186\/s12885-015-1632-z","article-title":"Organ preservation in rectal adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management","volume":"15","author":"Smith","year":"2015","journal-title":"BMC Cancer"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"113356","DOI":"10.1016\/j.ejca.2023.113356","article-title":"Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer","volume":"194","author":"Fox","year":"2023","journal-title":"Eur J Cancer"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"133","DOI":"10.6004\/jnccn.2022.7071","article-title":"Prevalent pseudoprogression and pseudoresidue in patients with rectal cancer treated with neoadjuvant immune checkpoint inhibitors","volume":"21","author":"Xie","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite Instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1245\/s10434-018-6462-1","article-title":"AJCC 8th Edition: colorectal Cancer","volume":"25","author":"Weiser","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"h5527","DOI":"10.1136\/bmj.h5527","article-title":"STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies","volume":"351","author":"Bossuyt","year":"2015","journal-title":"Bmj"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00261-016-0805-9","article-title":"Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy","volume":"41","author":"Iannicelli","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12885-022-09348-z","article-title":"Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective, multicentre, double-arm, phase II trial (TORCH)","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"R32-20260109","doi-asserted-by":"crossref","first-page":"goae027","DOI":"10.1093\/gastro\/goae027","article-title":"Can rectal MRI and endorectal ultrasound accurately predict the complete response to neoadjuvant immunotherapy for rectal cancer?","volume":"12","author":"Zhai","year":"2024","journal-title":"Gastroenterol Rep"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"1149122","DOI":"10.3389\/fimmu.2023.1149122","article-title":"Total neoadjuvant treatment and PD-1\/PD-L1 checkpoint inhibitor in locally advanced rectal cancer","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Immunol"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s40425-019-0634-9","article-title":"Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination","volume":"7","author":"Grapin","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R35-20260109","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41571-019-0238-9","article-title":"Assessing the interactions between radiotherapy and antitumour immunity","volume":"16","author":"Grassberger","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","article-title":"Radiotherapy and immunotherapy: open questions and future strategies","volume":"8","author":"Pointer","year":"2022","journal-title":"Trends Cancer"},{"key":"R37-20260109","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Park","year":"2020","journal-title":"Radiology"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.2174\/0929867326666190507084839","article-title":"Circulating biomarkers for response prediction of rectal cancer to neoadjuvant chemoradiotherapy","volume":"27","author":"Bedin","year":"2020","journal-title":"Curr Med Chem"},{"key":"R42-20260109","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejso.2021.08.034","article-title":"ctDNA on liquid biopsy for predicting response and prognosis in locally advanced rectal cancer: a systematic review","volume":"48","author":"Morais","year":"2022","journal-title":"Eur J Surg Oncol"},{"key":"R43-20260109","first-page":"e22972","article-title":"High neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and low lymphocyte levels are correlated with worse pathological complete response rates","volume":"14","author":"Karakaya","year":"2022","journal-title":"Cureus"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.2217\/fon-2019-0389","article-title":"Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer","volume":"15","author":"Li","year":"2019","journal-title":"Future Oncol"},{"key":"R45-20260109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41416-022-01786-7","article-title":"MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer","volume":"127","author":"Song","year":"2022","journal-title":"Br J Cancer"},{"key":"R46-20260109","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1097\/JS9.0000000000001152","article-title":"Evaluation of transrectal ultrasound-guided tru-cut biopsy as a complementary method for predicting pathological complete response in rectal cancer after neoadjuvant treatment: a phase II prospective and diagnostic trial","volume":"110","author":"Huang","year":"2024","journal-title":"Int J Surg"},{"key":"R47-20260109","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/DCR.0000000000000329","article-title":"Endoscopic ultrasound-guided fine needle aspiration is highly accurate for the diagnosis of perirectal recurrence of colorectal cancer","volume":"58","author":"Fernandez-Esparrach","year":"2015","journal-title":"Dis Colon Rectum"},{"key":"R48-20260109","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2589-7500(21)00215-6","article-title":"Development and validation of a radiopathomics model to predict pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a multicentre observational study","volume":"4","author":"Feng","year":"2022","journal-title":"Lancet Digit Health"},{"key":"R49-20260109","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s11547-024-01796-w","article-title":"Image-based artificial intelligence for the prediction of pathological complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer: a systematic review and meta-analysis","volume":"129","author":"Shen","year":"2024","journal-title":"Radiol Med"},{"key":"R50-20260109","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00432-024-05876-2","article-title":"Deep learning model based on endoscopic images predicting treatment response in locally advanced rectal cancer undergo neoadjuvant chemoradiotherapy: a multicenter study","volume":"150","author":"Zhang","year":"2024","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:02:24Z","timestamp":1767963744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000002795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000002795","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]},"assertion":[{"value":"2025-02-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}